Nifedipine CR and sacubitril valsartan combo alleviates progression of diabetic nephropathy with hypertension

Diabetic nephropathy is a frequent complication of type 2 diabetes, often aggravated by hypertension. In this study, the combination of nifedipine and sacubitril valsartan proved to be promising in addressing the intricate health concerns associated with these conditions. The treatment showcased improvements in renal and endothelial function, reducing inflammation and positively influencing clinical indicators.

The study's outcomes indicate that the combination of nifedipine controlled-release tablets and sacubitril valsartan presents a potential avenue to alleviate the progression of diabetic nephropathy in the presence of hypertension. With favourable outcomes and minimal adverse effects, this approach offers a glimpse of hope for individuals grappling with these complex health issues. As researchers delve deeper into this treatment approach, further investigations and clinical trials are warranted to validate its efficacy and safety.

Reference:

Wei, Y., Hu, L., & Liu, G. (2023). Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension. International Immunopharmacology, 123(110755), 110755. https://doi.org/10.1016/j.intimp.2023.110755